Life Science Compliance Update

The Department of Health and Human Services has issued an Interim Final Rule, adjusting for inflation the maximum civil monetary…

Life sciences companies continue to be the target of whistleblower actions, not only on the federal level but the state level as…

There has been much hubbub around the Yates Memorandum and what it means for compliance officers, especially in the life sciences…

Opioids are under the microscope by a variety of groups, including political and pharmaceutical organizations. Now, adding fuel to…

A large number of pharmaceutical companies across Europe had until June 30, 2016 to disclose their financial interactions with…

As part of a three-part series on the Average Manufacturer Price (AMP), this month’s article explores the continuing and evolving…

Within the pharmaceutical industry there are new operating models emerging. One form of emerging arrangement is the increasing use…

In the AseraCare case, the United States Department of Justice (DOJ) sought to show that AseraCare submitted false claims. Relying…

Recent plaintiff wins in lawsuits against life sciences companies seeking to recover lost shareholder value resulting from…

Three years ago, EFPIA adopted the EFPIA transparency code. Now three years later, this article takes the opportunity to look at…